UK's nonclinical roadmap: MHRA joins global regulatory shift toward NAMs with detailed goals and timelines

This blog is part of The Regulatory Navigator series, where we explore the evolving regulatory landscape with actionable insight from Parexel's experts, sharing their experience to maximize success for clinical development and patient access.

Introduction 

The UK government recently issued a press release which outlines an ambitious strategy to accelerate the transition away from traditional animal testing toward New Approach Methodologies (NAMs).^1,2 This strategy represents a significant evolution in regulatory thinking that could influence global approaches to drug safety and efficacy assessment. 

The Medicines and Healthcare products Regulatory Agency (MHRA) is set to play a crucial role in the UK strategy. By outlining specific timelines, the UK, with the MHRA at its center, is moving beyond aspirational goals to actionable regulatory commitments, while providing clarity to the pharmaceutical industry on the path forward for implementing NAMs into their development programs. 

Role of the MHRA in advancing NAMs  

The MHRA will encourage the use of NAMs by developers of medicinal products; and ensure that NAMs are scientifically valid, reproducible and are predictive for humans. The MHRA will also ensure that its regulatory guidance aligns with advancements in this field.  To achieve these aims, in collaboration with key stakeholders, the MHRA will undertake the following activities: 

Table 1. MHRA strategic initiatives to advance NAMs 

UK timeline for targeted replacement of in vivo studies 

The UK government, along with the MHRA and other UK regulatory bodies, have identified an initial list of animal tests or methods which can be progressively phased out. Some of the animal studies targeted for replacement over the next 5 years are outlined below: 

Table 2. UK plan to phase out select animal tests (2025–2030) 

Preparing for transition to NAMs  

Although it will take several years to significantly phase out use of animal studies in drug development, the objectives set out in the UK strategy encourage pharmaceutical companies to take proactive and collaborative steps in preparation for this shift.  

Immediate actions drug developers can take include:  

Conduct a comprehensive audit of your current nonclinical development plan to identify areas where NAMs could be implemented in lieu of or in addition to in vivo studies, and whether such changes align with the UK timelines for phasing out of animal testing.^1,2  

Gain expertise in the types, development and validation of NAMs; or collaborate with experts in CROs and/or academic institutions. 

Engage early with the MHRA to understand qualification of a NAM for a given context of use, the agreed routes for method validation via the UKCAM or other organization, and the Scientific Advice procedures to gain MHRA feedback for NAMs during product development. 

In the longer term, as the MHRA and other regulators formally transition to specific NAMs, drug developers may need to develop a transition plan for their nonclinical programs that aligns with the UK/MHRA timeline for phasing out specific animal tests and accommodates the differing rates of NAMs adoption across global authorities.  

Conclusion 

The UK strategy for replacing animal studies with alternative methods is a bold advancement in drug development that is anticipated to provide better predictive value for drug safety and efficacy, while reducing animal testing.  The UK strategy and MHRA initiatives represent both a challenge and an opportunity for pharmaceutical companies. Early engagement and collaboration with regulators will be crucial for success. Companies that seek regulators’ advice early on how to integrate NAMs into their development programs will be better positioned to navigate the evolving global requirements.^5,6,7,8,9,10  

For drug developers that are considering designing their nonclinical programs within the UK timeline, Parexel's regulatory experts offer valuable support. Our team, which includes former FDA, UK and EMA nonclinical assessors, has extensive experience in nonclinical development and a deep understanding of the progressive policies of regulatory agencies.   

Would you like to discuss how your organization can prepare for upcoming changes or explore specific NAMs that might be relevant to your development programs? We are always ready for a conversation.  

References  

1. Press release: Animal testing to be phased out faster as UK unveils roadmap for alternative methods, November 2025 
2. Policy paper: Replacing animals in science: A strategy to support the development, validation and uptake of alternative methods, November 2025 
3. Medicines & Healthcare products Regulatory Agency. Impact of AI on the regulation of medical products - Implementing the AI White Paper principles, April 2024 
4. EMA, EMA/27380/2024: Terms of Reference (ToR) for the International Medicines Regulators’ Working Group on 3Rs, October 2024 
5. FDA, FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs, April 2025 
6. FDA, FDA Releases Draft Guidance on Reducing Testing on Non-Human Primates for Monoclonal Antibodies, December 2025 
7. FDA, Guidance for Industry: Monoclonal Antibodies: Streamlined Nonclinical Safety Studies, December 2025 
8. EMA, Reflection paper on the current regulatory testing requirements for medicinal products for human use and opportunities for implementation of the 3Rs, December 2024 
9. EMA, Reflection paper on non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation, October 2025 
10. EMA, The European medicines agencies network strategy 2028, March 2025 

Return to Insights Center